ArticleDiscover oncology2025
Prognostic significance of circulating tumor DNA in non-metastatic colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeCirculating tumor DNA (ctDNA) is the small fragments of DNA released by tumor cells into the blood. By detecting the abnormal changes in ctDNA in the blood, it can assist in the early screening of cancer, monitoring of treatment efficacy, early warning of recurrence, and guidance for individualized treatment. Using a systematic review and meta-analysis approach, in this study, we assessed the significant prognostic value of ctDNA in non-metastatic colorectal cancer (CRC) patients.
methodsStudies on the predictive value of ctDNA in CRC were considered. RevMan 5.3 was used to conduct meta-analyses and subgroup investigations classified by tumor population, two-year or three-year DFS, and tumor location. The analysis included 11 trials conducted with 605 individuals. Definitions of positive ctDNA: Detection of ≥ 1 tumor-informed mutation, or tumor methylation signature above threshold, or combined mutation and fragmentome analysis.
resultsFive studies investigated the associations between pre-operative ctDNA status and patient outcomes. Patients who had higher ctDNA levels had considerably lower DFS and OS, but these differences were not statistically significant. 10 studies investigated how post-operative ctDNA status affects patient outcomes. Patients with high levels of ctDNA had worse DFS and OS, regardless of the tumor population, two-year DFS, three-year DFS, or tumor location. Surgical resection or chemotherapy increased the rate of ctDNA+/-. The study was registered on PROSPERO (CRD42024575151).
conclusionPost-operative ctDNA positivity is related to a poor outcome. Surgical excision or chemotherapy influences the ctDNA shift status. Circulating tumor DNA can serve as a promising prognostic indicator for patients with non-metastatic colorectal cancer. However, more studies are needed to assess the potential of ctDNA status with survival outcomes in Non-metastatic colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.